BMS's novel immunotherapy ipilimumab could gain US approval this year for melanoma
This article was originally published in Scrip
Bristol-Myers Squibb's novel immunotherapy ipilimumab could become the first new therapy approved for melanoma in more than a decade in the US after the FDA accepted the BLA for the treatment of previously treated advanced melanoma and also designated the filing a priority review.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.